These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. What's next for Alzheimer treatment?: while Aβ isn't out of the picture yet, several other therapeutic routes are being explored. Schwartz A Ann Neurol; 2013 Apr; 73(4):A7-9. PubMed ID: 24643982 [No Abstract] [Full Text] [Related]
8. J&J's billion dollar punt on anti-amyloid antibody. Sheridan C Nat Biotechnol; 2009 Aug; 27(8):679-81. PubMed ID: 19668155 [No Abstract] [Full Text] [Related]
9. Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice. Thomas R; Zuchowska P; Morris AW; Marottoli FM; Sunny S; Deaton R; Gann PH; Tai LM Acta Neuropathol Commun; 2016 Oct; 4(1):111. PubMed ID: 27788676 [TBL] [Abstract][Full Text] [Related]
10. Oligodendrocytes take centre stage in APOE4-linked Alzheimer disease. Kingwell K Nat Rev Drug Discov; 2023 Jan; 22(1):15. PubMed ID: 36446913 [No Abstract] [Full Text] [Related]
11. Structural differences of amyloid-β fibrils revealed by antibodies from phage display. Droste P; Frenzel A; Steinwand M; Pelat T; Thullier P; Hust M; Lashuel H; Dübel S BMC Biotechnol; 2015 Jun; 15():57. PubMed ID: 26084577 [TBL] [Abstract][Full Text] [Related]
12. Effects of APOE ε4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. Kim HJ; Ye BS; Yoon CW; Cho H; Noh Y; Kim GH; Choi YS; Kim JH; Jeon S; Lee JM; Kim JS; Choe YS; Lee KH; Kim ST; Kim C; Kang DR; Ki CS; Lee JH; Werring DJ; Weiner MW; Na DL; Seo SW Neurobiol Aging; 2013 Nov; 34(11):2482-7. PubMed ID: 23769398 [TBL] [Abstract][Full Text] [Related]
13. Peripheral Inflammation, Apolipoprotein E4, and Amyloid-β Interact to Induce Cognitive and Cerebrovascular Dysfunction. Marottoli FM; Katsumata Y; Koster KP; Thomas R; Fardo DW; Tai LM ASN Neuro; 2017; 9(4):1759091417719201. PubMed ID: 28707482 [TBL] [Abstract][Full Text] [Related]
14. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Takata K; Hirata-Fukae C; Becker AG; Chishiro S; Gray AJ; Nishitomi K; Franz AH; Sakaguchi G; Kato A; Mattson MP; Laferla FM; Aisen PS; Kitamura Y; Matsuoka Y Eur J Neurosci; 2007 Nov; 26(9):2458-68. PubMed ID: 17970733 [TBL] [Abstract][Full Text] [Related]
15. A call for new thoughts about what might influence human brain aging: aging, apolipoprotein E, and amyloid. DeCarli C JAMA Neurol; 2015 May; 72(5):500-2. PubMed ID: 25775040 [No Abstract] [Full Text] [Related]
16. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. Lee HG; Zhu X; Castellani RJ; Nunomura A; Perry G; Smith MA J Pharmacol Exp Ther; 2007 Jun; 321(3):823-9. PubMed ID: 17229880 [TBL] [Abstract][Full Text] [Related]
17. Pathological synergism between amyloid-beta and apolipoprotein E4--the most prevalent yet understudied genetic risk factor for Alzheimer's disease. Belinson H; Michaelson DM J Alzheimers Dis; 2009; 17(3):469-81. PubMed ID: 19363257 [TBL] [Abstract][Full Text] [Related]
18. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models. Huang Y Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325 [TBL] [Abstract][Full Text] [Related]